Advertisement

Topics

Boehringer Ingelheim begins patient enrollment in VOLTAIRE─X study on interchangeability between adalimumab biosimilar candidate & Humira

09:41 EDT 29 Jul 2017 | PharmaBiz

Boehringer Ingelheim has announced that the first patient has been enrolled into its VOLTAIRE─X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the

Original Article: Boehringer Ingelheim begins patient enrollment in VOLTAIRE─X study on interchangeability between adalimumab biosimilar candidate & Humira

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim begins patient enrollment in VOLTAIRE─X study on interchangeability between adalimumab biosimilar candidate & Humira"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...